Limits...
Easily manageable prognostic factors in 152 Chinese elderly acute myeloid leukemia patients: a single-center retrospective study.

Xu J, Chen T, Liu Y, Zhu H, Wu W, Shen W, Xu B, Qian S, Li J, Liu P - J Biomed Res (2014)

Bottom Line: Univariate analysis revealed similar results for OS to those of the log-rank test and only higher LDH at diagnosis was a significant adverse predictor for RFS (P  =  0.028, HR: 1.979, 95%CI: 1.075-3.644).Our data indicated that older age, gender and a previous history of hematologic diseases resulted in lower complete remission rate (P  =  0.012, 0.051 and 0.086, respectively).Patients who had lower scores showed significantly longer OS and RFS (P  =  0.0006 and 0.1001, respectively) and higher CR rate (P  =  0.014).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.

ABSTRACT
We retrospectively investigated the prognostic factors of acute myeloid leukemia (AML) in 152 Chinese patients with de novo AML who were older than 60 years of age and who received treatment at our hospital. Log-rank test showed that 6 parameters including older age, higher white blood cell (WBC) counts, lactate dehydrogenase (LDH) and bone marrow (BM) blasts at diagnosis, unfavorable risk cytogenetics, and non-mutated CEBPα were significant adverse prognostic factors of overall survival (OS) for elderly AML patients (P  =  0.0013, 0.0358, 0.0132, 0.0242, 0.0236 and 0.0130, respectively). Moreover, older age and higher LDH were significant adverse predictors for relapse-free survival (RFS) (P  =  0.0447 and 0.0470, respectively). Univariate analysis revealed similar results for OS to those of the log-rank test and only higher LDH at diagnosis was a significant adverse predictor for RFS (P  =  0.028, HR: 1.979, 95%CI: 1.075-3.644). In multivariate analysis, we identified 2 trends towards independent prognostic factors for OS, including BM blasts at diagnosis (P  =  0.057, HR: 1.676, 95%CI: 0.984-2.854) and mutation status of CEBPα (P  =  0.064, HR: 4.173, 95%CI: 0.918-18.966). Our data indicated that older age, gender and a previous history of hematologic diseases resulted in lower complete remission rate (P  =  0.012, 0.051 and 0.086, respectively). We further developed an easy scoring system for predicting prognosis and response to induction therapy in older AML patients. Patients who had lower scores showed significantly longer OS and RFS (P  =  0.0006 and 0.1001, respectively) and higher CR rate (P  =  0.014). Our research is limited by its retrospective nature and the results from our study need to be further validated by prospective randomized clinical trials.

No MeSH data available.


Related in: MedlinePlus

The overall survival (OS) (green line) and relapse free survival (RFS) (red line) of 152 elderly patients with AML.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4197391&req=5

f01: The overall survival (OS) (green line) and relapse free survival (RFS) (red line) of 152 elderly patients with AML.

Mentions: The baseline characteristics of the 152 patients are listed in Table 1. The 152 patients included 97 death cases and 55 censored cases. The median OS was 6.2 months (range: 0.07 to 86.33 months). The median OS for patients receiving induction therapy was 7.9 months. The estimated 1-, 3-, and 5-year survival rates of the patients older than 60 years were 49.1%, 22.2% and 8.2%, respectively (Fig. 1). In patients receiving chemotherapy, CR was achieved in 69 of 115 cases (60.0%). Among 69 patients who achieved CR, 15 were lost to follow up. In the remaining 54 patients, 37 (68.5%) relapsed. The RFS of the 54 patients ranged from 3 days to 5.6 years. The median RFS was 6.2 months (Fig. 1).


Easily manageable prognostic factors in 152 Chinese elderly acute myeloid leukemia patients: a single-center retrospective study.

Xu J, Chen T, Liu Y, Zhu H, Wu W, Shen W, Xu B, Qian S, Li J, Liu P - J Biomed Res (2014)

The overall survival (OS) (green line) and relapse free survival (RFS) (red line) of 152 elderly patients with AML.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4197391&req=5

f01: The overall survival (OS) (green line) and relapse free survival (RFS) (red line) of 152 elderly patients with AML.
Mentions: The baseline characteristics of the 152 patients are listed in Table 1. The 152 patients included 97 death cases and 55 censored cases. The median OS was 6.2 months (range: 0.07 to 86.33 months). The median OS for patients receiving induction therapy was 7.9 months. The estimated 1-, 3-, and 5-year survival rates of the patients older than 60 years were 49.1%, 22.2% and 8.2%, respectively (Fig. 1). In patients receiving chemotherapy, CR was achieved in 69 of 115 cases (60.0%). Among 69 patients who achieved CR, 15 were lost to follow up. In the remaining 54 patients, 37 (68.5%) relapsed. The RFS of the 54 patients ranged from 3 days to 5.6 years. The median RFS was 6.2 months (Fig. 1).

Bottom Line: Univariate analysis revealed similar results for OS to those of the log-rank test and only higher LDH at diagnosis was a significant adverse predictor for RFS (P  =  0.028, HR: 1.979, 95%CI: 1.075-3.644).Our data indicated that older age, gender and a previous history of hematologic diseases resulted in lower complete remission rate (P  =  0.012, 0.051 and 0.086, respectively).Patients who had lower scores showed significantly longer OS and RFS (P  =  0.0006 and 0.1001, respectively) and higher CR rate (P  =  0.014).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.

ABSTRACT
We retrospectively investigated the prognostic factors of acute myeloid leukemia (AML) in 152 Chinese patients with de novo AML who were older than 60 years of age and who received treatment at our hospital. Log-rank test showed that 6 parameters including older age, higher white blood cell (WBC) counts, lactate dehydrogenase (LDH) and bone marrow (BM) blasts at diagnosis, unfavorable risk cytogenetics, and non-mutated CEBPα were significant adverse prognostic factors of overall survival (OS) for elderly AML patients (P  =  0.0013, 0.0358, 0.0132, 0.0242, 0.0236 and 0.0130, respectively). Moreover, older age and higher LDH were significant adverse predictors for relapse-free survival (RFS) (P  =  0.0447 and 0.0470, respectively). Univariate analysis revealed similar results for OS to those of the log-rank test and only higher LDH at diagnosis was a significant adverse predictor for RFS (P  =  0.028, HR: 1.979, 95%CI: 1.075-3.644). In multivariate analysis, we identified 2 trends towards independent prognostic factors for OS, including BM blasts at diagnosis (P  =  0.057, HR: 1.676, 95%CI: 0.984-2.854) and mutation status of CEBPα (P  =  0.064, HR: 4.173, 95%CI: 0.918-18.966). Our data indicated that older age, gender and a previous history of hematologic diseases resulted in lower complete remission rate (P  =  0.012, 0.051 and 0.086, respectively). We further developed an easy scoring system for predicting prognosis and response to induction therapy in older AML patients. Patients who had lower scores showed significantly longer OS and RFS (P  =  0.0006 and 0.1001, respectively) and higher CR rate (P  =  0.014). Our research is limited by its retrospective nature and the results from our study need to be further validated by prospective randomized clinical trials.

No MeSH data available.


Related in: MedlinePlus